Evidence map›Paper›PMID 38339054›Full record

ArticleInternational journal of molecular sciences2024

Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.

Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara L Vine, Debbie Watson, Ronald Sluyter

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Xenogeneic Animal Models of Graft-Versus-Host Disease.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Peter CuthbertsonMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Amy ButtonMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Chloe SligarMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0002-9214-0742
Amal ElhageMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0003-0625-3183
Kara L VineMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0001-6871-1149
Debbie WatsonMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
Ronald SluyterMolecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0003-4909-686X
University of Wollongong · AU

Funding

Cancer Council New South Wales RG 19-12University of Wollongong T021
6 · The paper itself

Abstract

Allogeneic haematopoietic stem cell transplantation (HSCT) leads to the establishment of graft-versus-leukaemia (GVL) immunity, but in many cases also results in the development of graft-versus-host disease (GVHD). This study aimed to determine if P2X7 antagonism using Brilliant Blue G (BBG) could improve the beneficial effects of post-transplant cyclophosphamide (PTCy) in a humanised mouse model of GVHD, without comprising GVL immunity. NOD.Cg-

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemiaRosaniline DyesAnimalsCyclophosphamideHumansLeukocytes, MononuclearMiceMice, Inbred NODNeoplasm Recurrence, LocalRetrospective Studiescoomassie Brilliant BlueCyclophosphamideRosaniline Dyesacute myeloid leukaemiaadverse eventcytokineectonucleotidasegraft-versus-tumour immunitylymphocyteP2X7post-transplant cyclophosphamidepurinergic receptorxenogeneic graft-versus-host disease

Identifiers

PMID38339054
PMCPMC10855770
OpenAlexW4391449746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.